KRRO

Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.

Wall Street analysts forecast KRRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KRRO is 56.60 USD with a low forecast of 7.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Korro Bio Inc revenue for the last quarter amounts to 1.09M USD, decreased % YoY.

Korro Bio Inc. EPS for the last quarter amounts to -1.92 USD, decreased -15.04 % YoY.

Korro Bio Inc (KRRO) has 104 emplpoyees as of December 17 2025.

Today KRRO has the market capitalization of 77.41M USD.